Shield Therapeutics PLC logo

Shield Therapeutics PLC

LSE:STX (UK)  
£ 0.02 (+17.07%) May 23
At Loss
P/B:
0.51
Market Cap:
£ 18.77M ($ 23.91M)
Enterprise V:
£ 10.95M ($ 13.95M)
Volume:
23.73M
Avg Vol (2M):
4.50M
Also Trade In:
Volume:
23.73M
At Loss
Avg Vol (2M):
4.50M

Business Description

Description
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 2.36
Equity-to-Asset 0.65
Debt-to-Equity 0.21
Debt-to-EBITDA -0.17
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -14.58
Distress
Grey
Safe
Beneish M-Score -8.39
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 86.58
9-Day RSI 78.14
14-Day RSI 70.1
6-1 Month Momentum % -76.25
12-1 Month Momentum % -79.2

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.95
Quick Ratio 2.64
Cash Ratio 1.53
Days Inventory 198.56
Days Sales Outstanding 324.65
Days Payable 451.48

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -29.1
Shareholder Yield % -189.73

Financials (Next Earnings Date:2024-09-27 Est.)

LSE:STX's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Shield Therapeutics PLC Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil £) 6.187
EPS (TTM) (£) -0.12
Beta 2.18
Volatility % 101.73
14-Day RSI 70.1
14-Day ATR (£) 0.002219
20-Day SMA (£) 0.016913
12-1 Month Momentum % -79.2
52-Week Range (£) 0.01063 - 0.1285
Shares Outstanding (Mil) 782.06

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Shield Therapeutics PLC Filings

Filing Date Document Date Form
No Filing Data

Shield Therapeutics PLC Stock Events

Financials Calendars
Event Date Price(£)
No Event Data

Shield Therapeutics PLC Frequently Asked Questions

What is Shield Therapeutics PLC(LSE:STX)'s stock price today?
The current price of LSE:STX is £0.02. The 52 week high of LSE:STX is £0.13 and 52 week low is £0.01.
When is next earnings date of Shield Therapeutics PLC(LSE:STX)?
The next earnings date of Shield Therapeutics PLC(LSE:STX) is 2024-09-27 Est..
Does Shield Therapeutics PLC(LSE:STX) pay dividends? If so, how much?
Shield Therapeutics PLC(LSE:STX) does not pay dividend.

Press Release

Subject Date
No Press Release